Research & Development
Predicine to present posters on liquid biopsy tech at ESMO
Predicine's liquid biopsy portfolio includes assays that provide translational insights to aid in potential cancer therapeutic strategies.
September 8, 2022
Combining imaging with liquid biopsy for cervical cancer
The authors -- researchers at the University of California San Diego (UCSD) and Johns Hopkins University -- noted that liquid biopsy has emerged as a promising tool that may be able to overcome some of imaging's drawbacks.
August 22, 2022
Thermo Fisher, Guardant Health get approval for NSCLC CDx
Enhertu is an HER2-directed antibody drug conjugate being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
August 11, 2022
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
Biodesix touts VeriStrat test results
The blood-based test was predictive of progression-free survival and overall survival in patients with non-small cell lung cancer with low or negative PD-L1 treated with immune checkpoint inhibitors, the firm said.
July 19, 2022
BillionToOne launches liquid biopsy products for research
The products are available for research use in select academic cancer centers.
July 7, 2022
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
Quest Diagnostics offers suite of services for transplant patients and living donors
Simple blood test can detect PTSD biomarkers
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Illumina NGS software to enable tertiary analysis for oncology, rare disease
Serum protein in study predicted which patients might die without a liver transplant
Biocartis, AstraZeneca to develop CDx for EGFR TKI treatment
The firms aim to obtain applicable premarket notification or approval from the U.S. Food and Drug Administration (FDA) for a CDx test on Biocartis' fully automated molecular Idylla platform.
June 21, 2022
Foundation Medicine gets FDA nod for NSCLC CDx
Rozlytrek is a targeted therapy for the treatment of non-small cell lung cancer (NSCLC) developed by Roche's Genentech.
June 8, 2022
Karius, Capstone Health widen access to liquid biopsy test
According to Karius, the new partnership will also broaden access to microbial cell-free metagenomics technology used in the liquid biopsy-based, lab-developed test.
June 8, 2022
Tempus launching liquid biopsy panel
The company said it will initially make the test available on a limited scale along with its xF 105-gene liquid biopsy assay and conduct a broader launch later in 2022.
June 5, 2022
Bristol Myers Squibb promotes ctDNA liquid biopsy study
BMS scientists demonstrated that Predicine's PredicineAtlas liquid biopsy next-generation sequencing (NGS) assay outperformed four other tests in detection sensitivity, specificity, accuracy, and reproducibility. The Precidine assay also proved capable of identifying gene deletion or copy number reductions in the study, Bristol Myers Squibb said.
May 17, 2022
Artemis signs $250M deal for liquid biopsy tests with Datar
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
Page 1 of 5